Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

Obinutuzumab is a type 2, glycoengineered, anti-CD20 antibody recently approved with chlorambucil for the initial therapy of chronic lymphocytic leukemia (CLL). In this nonrandomized, parallel-cohort, phase 1b, multicenter study, we explored the safety and preliminary efficacy of obinutuzumab-bendam...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Brown, Jennifer R., O’Brien, Susan, Kingsley, C. Daniel, Eradat, Herbert, Pagel, John M., Lymp, James, Hirata, Jamie, Kipps, Thomas J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2015
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4416529/
https://ncbi.nlm.nih.gov/pubmed/25769620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-12-613570
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg